Immunic, inc. reports year end 2021 financial results and highlights recent activity

New york, feb. 24, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended december 31, 2021 and highlighted recent activity. "2021 was another year of tremendous achievement for immunic, punctuated by significant clinical progress across our key pipeline programs, including our lead product candidate, selective oral dhodh inhibitor, vidofludimus calcium (imu-838) and imu-935, a highly potent and selective oral il-17 inhibitor.
IMUX Ratings Summary
IMUX Quant Ranking